5 septiembre 2014
Restarting infliximab therapy after a drug holiday is safe and effective for patients with inflammatory bowel disease (IBD), according to a new study. Infliximab was the first anti-tumor necrosis factor biologic for Crohn’s disease and still is used frequently for its efficacy in both Crohn’s and ulcerative colitis. Studies have shown that loss of response to infliximab is about 13 percent per patient-year of treatment.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/jCxPI_d-GWU/140905090617.htm
